The Global Tuberculosis Institute (GTBI) was established to advance state-of-the-art care for tuberculosis through excellence in research, practice and teaching. Since 1995, GTBI has conducted multiple protocols and sub-trials for the Centers for Disease Control and Prevention (CDC) Tuberculosis Clinical Trials Consortium (TBTC) and TB Epidemiologic Trial Consortium (TBESC). With extensive experience in domestic field trials and collaborative work in high TB burden countries, GTBI utilizes its unique capacities of scientific expertise and technical assistance to continue its mission to conduct relevant tuberculosis clinical trials and translational research.

With grants from the National Institutes of Health, National Institute of Allergy and Infectious Diseases, New Jersey Health Foundation and other agencies, over the last five years GTBI has increased its collaboration with investigators at the Public Health Research Institute (PHRI) to pursue TB research that encompasses various areas of biomedical investigation and public health. Currently, there are three active protocols focused on developing novel platforms for TB diagnosis, understanding sputum macrophage lipid metabolism markers association with TB disease severity and another which hopes to better understand humoral responses in TB.

TB research at Rutgers University is not just limited to GTBI and PHRI, but to others who have contributed to growing recent advances in TB diagnostics, treatment, and drug resistance.